Mavrikakis M E, Sfikakis P P, Kontoyannis D, Horti M, Kittas C, Koutras D A, Raptis S A
Department of Clinical Therapeutics, Alexandra Hospital, Athens, Greece.
Exp Clin Endocrinol Diabetes. 1998;106(1):35-40. doi: 10.1055/s-0029-1211947.
The aim of this study was to demonstrate the macrovascular disease in streptozotocin-induced diabetic rats and assess any possible differences between the histopatholological changes of the coronaries and cerebral arteries. Hearts and brains were obtained after 4 weeks (short-term experimental diabetes, 10 rats) and 12 weeks (long-term experimental diabetes, 10 rats) of streptozotocin injection. Sham injected, control rats were studied in parallel. Muscular-type arteries of 0.10-0.15 mm were examined and semiquantitatively classified either as normal, or slightly, or moderately, or severely thickened by light microscopy: While the arterial wall appeared normal in all sham-injected rats, a varying degree of hyperplasia of the muscular layer and deposition of fibrinoid material resulting in arterial stenosis was prominent in streptozotocin-injected rats. In the group of short-term diabetes there was a slight thickening of the cerebral arteries in the majority of the rats (8/10 rats), while thickening of the coronaries was moderate (9/10 rats). Further progression of arterial wall thickening in both cerebral and coronary arteries was observed in the long-term diabetic group. The mean severity of lesions was significantly higher in the coronaries than in cerebral arteries, both in the short-term (p < 0.0005) and long-term diabetes (p < 0.02). Moreover, by paired statistics within individual animals, we confirmed that wall thickening was significantly more severe in coronaries than cerebral arteries in both groups. These findings suggest an accelerated progress of macrovascular disease in the heart as compared to the brain in the streptozotocin-induced diabetic rat. Although histopathological changes in humans do not always mirror clinical severity, the differences in the macrovascular disease between heart and brain in experimental diabetes may be relevant to the higher relative risk of myocardial infarction compared to stroke for people with diabetes, as compared to people without diabetes.
本研究的目的是证实链脲佐菌素诱导的糖尿病大鼠的大血管疾病，并评估冠状动脉和脑动脉组织病理学变化之间的任何可能差异。在注射链脲佐菌素4周（短期实验性糖尿病，10只大鼠）和12周（长期实验性糖尿病，10只大鼠）后获取心脏和大脑。对假注射的对照大鼠进行平行研究。检查直径为0.10 - 0.15毫米的肌型动脉，并通过光学显微镜进行半定量分类，分为正常、轻度、中度或重度增厚：在所有假注射大鼠中动脉壁看起来正常，而在注射链脲佐菌素的大鼠中，肌层不同程度的增生和类纤维蛋白物质沉积导致动脉狭窄很明显。在短期糖尿病组中，大多数大鼠（8/10只大鼠）脑动脉有轻微增厚，而冠状动脉增厚为中度（9/10只大鼠）。在长期糖尿病组中观察到脑动脉和冠状动脉壁增厚进一步进展。无论是短期（p < 0.0005）还是长期糖尿病（p < 0.02），冠状动脉病变的平均严重程度均显著高于脑动脉。此外，通过对个体动物进行配对统计，我们证实两组中冠状动脉壁增厚均明显比脑动脉更严重。这些发现表明，在链脲佐菌素诱导的糖尿病大鼠中，与大脑相比，心脏大血管疾病进展加速。尽管人类的组织病理学变化并不总是反映临床严重程度，但实验性糖尿病中心脏和大脑大血管疾病的差异可能与糖尿病患者与非糖尿病患者相比心肌梗死相对风险高于中风有关。
